Overall, the proportion of mutations in genes was lower in the low-risk group compared to the high-risk group, except for IDH1, TP53, ATRX and CIC. Furthermore, we evaluated genomic instability metrics: Tumor Mutation Burden (TMB, Figure 4C), MSIsensor Score (Figure 4D), Fraction Genome Altered (FGA, Figure 4E), Mutation Count (Figure 4F), and Homologous Recombination Deficiency (HRD) score (Figure 4G). This evidence concerns the gene IDH1 and neoplasm.